We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Halozyme Therapeutics (HALO - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Halozyme Therapeutics is one of 914 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Halozyme Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for HALO's full-year earnings has moved 3.4% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, HALO has gained about 51.3% so far this year. At the same time, Medical stocks have gained an average of 3.2%. As we can see, Halozyme Therapeutics is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Brookdale Senior Living (BKD - Free Report) . The stock is up 20.3% year-to-date.
Over the past three months, Brookdale Senior Living's consensus EPS estimate for the current year has increased 160%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Halozyme Therapeutics is a member of the Medical - Biomedical and Genetics industry, which includes 439 individual companies and currently sits at #152 in the Zacks Industry Rank. On average, this group has gained an average of 5.9% so far this year, meaning that HALO is performing better in terms of year-to-date returns.
In contrast, Brookdale Senior Living falls under the Medical - Nursing Homes industry. Currently, this industry has 2 stocks and is ranked #9. Since the beginning of the year, the industry has moved +7.6%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Halozyme Therapeutics and Brookdale Senior Living as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Halozyme Therapeutics (HALO - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Halozyme Therapeutics is one of 914 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Halozyme Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for HALO's full-year earnings has moved 3.4% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, HALO has gained about 51.3% so far this year. At the same time, Medical stocks have gained an average of 3.2%. As we can see, Halozyme Therapeutics is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Brookdale Senior Living (BKD - Free Report) . The stock is up 20.3% year-to-date.
Over the past three months, Brookdale Senior Living's consensus EPS estimate for the current year has increased 160%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Halozyme Therapeutics is a member of the Medical - Biomedical and Genetics industry, which includes 439 individual companies and currently sits at #152 in the Zacks Industry Rank. On average, this group has gained an average of 5.9% so far this year, meaning that HALO is performing better in terms of year-to-date returns.
In contrast, Brookdale Senior Living falls under the Medical - Nursing Homes industry. Currently, this industry has 2 stocks and is ranked #9. Since the beginning of the year, the industry has moved +7.6%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Halozyme Therapeutics and Brookdale Senior Living as they could maintain their solid performance.